Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 122

Related Citations for PubMed (Select 23041206)


T cell subsets and colorectal cancer: discerning the good from the bad.

Scurr M, Gallimore A, Godkin A.

Cell Immunol. 2012 Sep;279(1):21-4. doi: 10.1016/j.cellimm.2012.08.004. Epub 2012 Sep 14. Review.


Intratumoral CD8(+) T/FOXP3 (+) cell ratio is a predictive marker for survival in patients with colorectal cancer.

Suzuki H, Chikazawa N, Tasaka T, Wada J, Yamasaki A, Kitaura Y, Sozaki M, Tanaka M, Onishi H, Morisaki T, Katano M.

Cancer Immunol Immunother. 2010 May;59(5):653-61. doi: 10.1007/s00262-009-0781-9. Epub 2009 Nov 12.


Highly prevalent colorectal cancer-infiltrating LAP⁺ Foxp3⁻ T cells exhibit more potent immunosuppressive activity than Foxp3⁺ regulatory T cells.

Scurr M, Ladell K, Besneux M, Christian A, Hockey T, Smart K, Bridgeman H, Hargest R, Phillips S, Davies M, Price D, Gallimore A, Godkin A.

Mucosal Immunol. 2014 Mar;7(2):428-39. doi: 10.1038/mi.2013.62. Epub 2013 Sep 25.


Accumulation of foxp3+ T regulatory cells in draining lymph nodes correlates with disease progression and immune suppression in colorectal cancer patients.

Deng L, Zhang H, Luan Y, Zhang J, Xing Q, Dong S, Wu X, Liu M, Wang S.

Clin Cancer Res. 2010 Aug 15;16(16):4105-12. doi: 10.1158/1078-0432.CCR-10-1073. Epub 2010 Aug 3.


Identification of CD8+CD25+Foxp3+ suppressive T cells in colorectal cancer tissue.

Chaput N, Louafi S, Bardier A, Charlotte F, Vaillant JC, Ménégaux F, Rosenzwajg M, Lemoine F, Klatzmann D, Taieb J.

Gut. 2009 Apr;58(4):520-9. doi: 10.1136/gut.2008.158824. Epub 2008 Nov 20.


An increased abundance of tumor-infiltrating regulatory T cells is correlated with the progression and prognosis of pancreatic ductal adenocarcinoma.

Tang Y, Xu X, Guo S, Zhang C, Tang Y, Tian Y, Ni B, Lu B, Wang H.

PLoS One. 2014 Mar 17;9(3):e91551. doi: 10.1371/journal.pone.0091551. eCollection 2014.


Tumor-infiltrating FOXP3+ T regulatory cells show strong prognostic significance in colorectal cancer.

Salama P, Phillips M, Grieu F, Morris M, Zeps N, Joseph D, Platell C, Iacopetta B.

J Clin Oncol. 2009 Jan 10;27(2):186-92. doi: 10.1200/JCO.2008.18.7229. Epub 2008 Dec 8.


CD4(+)CD25(+)CD127(low/-) regulatory T cells express Foxp3 and suppress effector T cell proliferation and contribute to gastric cancers progression.

Shen LS, Wang J, Shen DF, Yuan XL, Dong P, Li MX, Xue J, Zhang FM, Ge HL, Xu D.

Clin Immunol. 2009 Apr;131(1):109-18. doi: 10.1016/j.clim.2008.11.010. Epub 2009 Jan 18.


The clinical utility of the local inflammatory response in colorectal cancer.

Richards CH, Roxburgh CS, Powell AG, Foulis AK, Horgan PG, McMillan DC.

Eur J Cancer. 2014 Jan;50(2):309-19. doi: 10.1016/j.ejca.2013.09.008. Epub 2013 Oct 5.


Tumor infiltration by T lymphocytes expressing chemokine receptor 7 (CCR7) is predictive of favorable outcome in patients with advanced colorectal carcinoma.

Correale P, Rotundo MS, Botta C, Del Vecchio MT, Ginanneschi C, Licchetta A, Conca R, Apollinari S, De Luca F, Tassone P, Tagliaferri P.

Clin Cancer Res. 2012 Feb 1;18(3):850-7. doi: 10.1158/1078-0432.CCR-10-3186. Epub 2011 Dec 5.


Activated but not resting regulatory T cells accumulated in tumor microenvironment and correlated with tumor progression in patients with colorectal cancer.

Lin YC, Mahalingam J, Chiang JM, Su PJ, Chu YY, Lai HY, Fang JH, Huang CT, Chiu CT, Lin CY.

Int J Cancer. 2013 Mar 15;132(6):1341-50. doi: 10.1002/ijc.27784. Epub 2012 Sep 18.


Enrichment of CCR6+Foxp3+ regulatory T cells in the tumor mass correlates with impaired CD8+ T cell function and poor prognosis of breast cancer.

Xu L, Xu W, Qiu S, Xiong S.

Clin Immunol. 2010 Jun;135(3):466-75. doi: 10.1016/j.clim.2010.01.014. Epub 2010 Feb 24.


Identification and characterization of Foxp3(+) gammadelta T cells in mouse and human.

Kang N, Tang L, Li X, Wu D, Li W, Chen X, Cui L, Ba D, He W.

Immunol Lett. 2009 Aug 15;125(2):105-13. doi: 10.1016/j.imlet.2009.06.005. Epub 2009 Jun 17.


High frequency of tumor-infiltrating FOXP3(+) regulatory T cells predicts improved survival in mismatch repair-proficient colorectal cancer patients.

Frey DM, Droeser RA, Viehl CT, Zlobec I, Lugli A, Zingg U, Oertli D, Kettelhack C, Terracciano L, Tornillo L.

Int J Cancer. 2010 Jun 1;126(11):2635-43. doi: 10.1002/ijc.24989.


The significance of Treg cells in defective tumor immunity.

Kosmaczewska A, Ciszak L, Potoczek S, Frydecka I.

Arch Immunol Ther Exp (Warsz). 2008 May-Jun;56(3):181-91. doi: 10.1007/s00005-008-0018-1. Epub 2008 May 30. Review.


Prognostic role of FOXP3+ regulatory T cells infiltrating human carcinomas: the paradox of colorectal cancer.

Ladoire S, Martin F, Ghiringhelli F.

Cancer Immunol Immunother. 2011 Jul;60(7):909-18. doi: 10.1007/s00262-011-1046-y. Epub 2011 Jun 5. Review.


T cell subpopulations in lymph nodes may not be predictive of patient outcome in colorectal cancer.

Kemp RA, Black MA, McCall J, Yoon HS, Phillips V, Anjomshoaa A, Reeve AE.

J Exp Clin Cancer Res. 2011 Aug 24;30:78. doi: 10.1186/1756-9966-30-78.


Immune microenvironment in colorectal cancer: a new hallmark to change old paradigms.

de la Cruz-Merino L, Henao Carrasco F, Vicente Baz D, Nogales Fernández E, Reina Zoilo JJ, Codes Manuel de Villena M, Pulido EG.

Clin Dev Immunol. 2011;2011:174149. doi: 10.1155/2011/174149. Epub 2011 Nov 24. Review.


LAG-3 expression defines a subset of CD4(+)CD25(high)Foxp3(+) regulatory T cells that are expanded at tumor sites.

Camisaschi C, Casati C, Rini F, Perego M, De Filippo A, Triebel F, Parmiani G, Belli F, Rivoltini L, Castelli C.

J Immunol. 2010 Jun 1;184(11):6545-51. doi: 10.4049/jimmunol.0903879. Epub 2010 Apr 26.


Foxp3 expression in melanoma cells as a possible mechanism of resistance to immune destruction.

Niu J, Jiang C, Li C, Liu L, Li K, Jian Z, Gao T.

Cancer Immunol Immunother. 2011 Aug;60(8):1109-18. doi: 10.1007/s00262-011-1025-3. Epub 2011 May 6.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk